WO2013124860A1 - Potent revital formulation - Google Patents
Potent revital formulation Download PDFInfo
- Publication number
- WO2013124860A1 WO2013124860A1 PCT/IN2013/000020 IN2013000020W WO2013124860A1 WO 2013124860 A1 WO2013124860 A1 WO 2013124860A1 IN 2013000020 W IN2013000020 W IN 2013000020W WO 2013124860 A1 WO2013124860 A1 WO 2013124860A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- potent
- revital
- oral formulation
- supports
- liver
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000009472 formulation Methods 0.000 title claims abstract description 36
- 230000003389 potentiating effect Effects 0.000 title claims abstract description 33
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 105
- 229960003080 taurine Drugs 0.000 claims abstract description 53
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940080308 racemethionine Drugs 0.000 claims abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 235000010755 mineral Nutrition 0.000 claims abstract description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 11
- 229930003231 vitamin Natural products 0.000 claims abstract description 11
- 235000013343 vitamin Nutrition 0.000 claims abstract description 11
- 239000011782 vitamin Substances 0.000 claims abstract description 11
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
- 239000011573 trace mineral Substances 0.000 claims abstract description 7
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 7
- 229910052742 iron Inorganic materials 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 61
- 210000004185 liver Anatomy 0.000 claims description 42
- 229960003180 glutathione Drugs 0.000 claims description 31
- 235000003969 glutathione Nutrition 0.000 claims description 30
- 108010024636 Glutathione Proteins 0.000 claims description 29
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 29
- 229930182817 methionine Natural products 0.000 claims description 28
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 27
- 229960001570 ademetionine Drugs 0.000 claims description 26
- 239000003963 antioxidant agent Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 235000006708 antioxidants Nutrition 0.000 claims description 22
- 230000006870 function Effects 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 230000003078 antioxidant effect Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 15
- 150000003254 radicals Chemical class 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 230000004224 protection Effects 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 210000000988 bone and bone Anatomy 0.000 claims description 11
- 210000003494 hepatocyte Anatomy 0.000 claims description 10
- 238000012423 maintenance Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 10
- 210000000653 nervous system Anatomy 0.000 claims description 10
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 9
- 206010067125 Liver injury Diseases 0.000 claims description 9
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000003405 preventing effect Effects 0.000 claims description 9
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000001784 detoxification Methods 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 230000003908 liver function Effects 0.000 claims description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims description 7
- 239000002243 precursor Substances 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 230000018109 developmental process Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000003925 fat Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003613 bile acid Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 229960001340 histamine Drugs 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- 230000001071 malnutrition Effects 0.000 claims description 3
- 235000000824 malnutrition Nutrition 0.000 claims description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052753 mercury Inorganic materials 0.000 claims description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000016938 Catalase Human genes 0.000 claims description 2
- 108010053835 Catalase Proteins 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003756 Vitamin B7 Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 230000036528 appetite Effects 0.000 claims description 2
- 235000019789 appetite Nutrition 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 230000000711 cancerogenic effect Effects 0.000 claims description 2
- 231100000315 carcinogenic Toxicity 0.000 claims description 2
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims description 2
- 230000004217 heart function Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000003212 lipotrophic effect Effects 0.000 claims description 2
- 230000007102 metabolic function Effects 0.000 claims description 2
- 230000004220 muscle function Effects 0.000 claims description 2
- 150000004005 nitrosamines Chemical class 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 210000004994 reproductive system Anatomy 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003495 thiamine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000011912 vitamin B7 Nutrition 0.000 claims description 2
- 239000011735 vitamin B7 Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- PWNBRRGFUVBTQG-UHFFFAOYSA-N 1-n,4-n-di(propan-2-yl)benzene-1,4-diamine Chemical compound CC(C)NC1=CC=C(NC(C)C)C=C1 PWNBRRGFUVBTQG-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 210000003007 myelin sheath Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 125000001452 riboflavin group Chemical group 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 abstract description 3
- 229960004452 methionine Drugs 0.000 description 28
- 208000019423 liver disease Diseases 0.000 description 16
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000036542 oxidative stress Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 208000028017 Psychotic disease Diseases 0.000 description 4
- 208000029650 alcohol withdrawal Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 239000008203 oral pharmaceutical composition Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- -1 oral irrigators Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 208000007232 portal hypertension Diseases 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000002970 ATP quantitation Methods 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940006423 chondroitin sulfate sodium Drugs 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229960002849 glucosamine sulfate Drugs 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- FYYHWMGAXLPEAU-OUBTZVSYSA-N magnesium-25 atom Chemical compound [25Mg] FYYHWMGAXLPEAU-OUBTZVSYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229940106205 potassium 20 mg Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Definitions
- the present invention relates to efficient oral pharmaceutical composition which comprises main active ingredients such as taurine and race methionine along with multivitamins, minerals, trace elements some pharmaceutically acceptable excipients preferably in oral dosage form.
- Alcohol is a powerful liver toxin that harms (damages) the liver in three stages: alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. About 20 percent of alcoholics and heavy drinkers develop fatty liver, or steatosis. The rate of mortality in severe cases is about 50 percent. If heavy drinking continues, about 40 percent of cases of alcoholic hepatitis will develop into cirrhosis.
- a nutritional product for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L- tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies
- EP1408988 wherein said Provided is a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage.
- a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage.
- compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin.
- This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
- the present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (herein after, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibres such as insulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
- LIV branched chain amino acids
- LIV branched chain amino
- an exemplary dried, meat-based product includes meat and plant seed where the plant seed comprises at least approximately 3% caffeine by weight.
- an exemplary product includes guarana plant seed.
- plant seed may be provided as a powder according to US 2009/0005320 Al wherein said The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di-peptide and a tri-peptide, and to methods of making and using said compositions.
- Certain amino acids have found to play a promising role in preventing and treating a majority of these liver diseases due to their antitoxic and antioxidant properties. Racemethionine and Taurine are vital amongst them.
- the invention is to provide commercially viable and efficient formulation.
- the invention is to provide safe and effective dosage form with taurine and racemethionine composition and other ingredients such as multivitamins, minerals, trace elements which are using as dietery supplements.
- the invention is to provide different release drug profile such as Sustained or controlled or retard formulation available in oral formulation (capsule, tablet, powder and in liquid thereof)
- the invention is to protect chronic illness or malnutrition may be due to defective nutrition, wherein patient is not able to take vitamins/ minerals / trace elements leads to poor performance of vital organs.
- it will provide instant energy and work like prophylactic total health care.
- liver protecting medication consists of amino acids, minerals, vitamins thereof can form spontaneously and are therefore thermodynamically stable.
- the present invention discloses the efficiency pharmaceutical composition in oral dosage form. This comprises therapeutically effective amount of taurine, racemethionine multivitamins, minerals thereof so as to make the formulation stable.
- the said oral pharmaceutical composition is available in various forms such as tablet, capsule, sachet, powder (liquid) thereof. It is useful supplementation in patients suffering from liver diseases and may also provide valuable benefits in patients suffering from cardiovascular diseases, diabetes, neurological disorders and others.
- Essential Amino Acids cannot manufacture these Amino Acids in body. These amino acids have antioxidant, antitoxic property which is useful in organ protection and detoxification of harmful substances. Racemethionine and Taurine are the examples of such amino acids.
- Taurine a liver protecting amino acid
- taurine is essential for formation of bile acids and thus for detoxification processes, it reduces the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis.
- taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions. It is useful in treating people with alcohol dependency and is a detoxifying agent with antioxidant action that helps protect liver cells against various toxins.
- taurine In the case of liver health wherein Taurine is known that the liver is the main organ for taurine biosynthesis and also an important target organ for taurine's many biological activities. It is essential for formation of bile acids and thus for detoxification processes. In a clinical study, taurine has been shown to reduce the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions.
- -Taurine increases levels of antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and ROS induced damages
- taurine As essential component of cell membranes wherein it enhances transport of important ions across hepatocytes thus improving their functions and recovery.
- a deficiency of taurine can lead to electrolyte imbalance due to impaired mineral transport across cell membranes and this reduces the ability of the liver to remove toxic substances.
- Tissue necotising factor alpha is a marker for inflammatory processes that leads to cell death. Taurine supplementation prevents these damages and protects cells.
- taurine pre-treatment prevents the morphologic damage caused by CC14 in the early stages.
- Taurine in alcoholic liver disorders wherein Taurine reverses the hepatic steatosis (deposition of fat) and lipid peroxidation caused by chronic alcohol consumption in rats
- taurine has been shown to be useful in treating people with alcohol dependency involving over 3,000 alcohol dependent people who were given taurine showed that taurine is more effective than placebo at preventing alcohol relapse.
- Taurine increases urine excretion of homocysteine during alcohol withdrawal.
- Rise in blood homocysteine hyperhomocysteinaemia
- Taurine being an inhibitory neurotransmitter reduces excitatory signals. It also reduces hyperhomocysteinaemia by excreting homocysteine through kidneys. This dual effect helps in alcohol withdrawal.
- racemethionine (2-amino-4-methylsulfanylbutanoic acid (C5H11N02S) is a lipotropic amino acid in hepatoprotection. It is a potent methyl donor, powerful antioxidant and a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe).
- Racemethionine is also the precursor for taurine and thus its levels are reduced due to consumption for formation of taurine.
- Taurine supplementation along with methionine increases liver taurine levels and spares methionine for other vital functions. This makes the combination of Taurine and Methionine as a viable (effective) combination with synergistic action.
- Methionine which has Methyl (-CH3) donor important in metabolic processes where methyl group is transferred to other compound (methylation).
- a precursor to other important substances like S-adenosyl methionine (SAMe), glutathione and amino acids like taurine and cysteine.
- Methionine levels determine the liver's concentration of sulfur- containing antioxidant compounds like SAMe and glutathione which improve and normalize liver functions.
- Methionine itself has a protective effect on glutathione and prevents depletion during toxic overload, which can protect the liver from the damaging effects of toxic compounds.
- Methionine residues on the surface of proteins (like enzymes) offer antioxidant protection and thus prevent degradation of proteins by reactive oxygen species and free radicals. Liver contains maximum amounts of enzymes and thus methionine concentration in liver is important for protection against toxic free radicals.
- Alcoholic liver disorder wherein Alcohol is a major cause of liver disease and disrupts methionine and oxidative balances.
- Methionine was found to strongly improve the alcohol-induced histological changes in the liver. Triglyceride content of the liver was found to decrease in a dose-dependent manner with increasing methionine ingestion.
- Hepatic adenosine triphosphate content increased significantly with higher methionine consumption.
- Methionine is the precursor for other important antioxidant substances like SAMe and glutathione.
- SAMe is an active compound made from methionine and adenosine triphosphate (ATP). It acts as a methyl donor in a variety of biochemical pathways. Methylation reactions are essential for the detoxification of harmful products of metabolism, and the synthesis of numerous physiological agents including neurotransmitters, cartilage, and glutathione. The role of SAMe for intrahepatic cholestasis associated with liver disease has been observed.
- SAMe improves and normalizes liver function.
- SAMe is used in the treatment of cirrhosis and liver damage caused by alcohol. Through methylation, SAMe increases membrane fluidity, restoring several factors that promote bile flow. Treatment with SAMe helps decrease serum bilirubin (pigment in the blood that can cause jaundice) in patients with elevated serum bilirubin level.
- SAMe S-Adenosyl-L-methionine
- SAMe exerts major key functions in the liver, including serving as a precursor for cysteine and glutathion.
- SAMe is particularly important in opposing the toxicity of free oxygen radicals generated by various pathogens, including alcohol, which causes oxidative stress largely by the induction of cytochrome P4502E1 (CYP2E1) and by its metabolite acetaldehyde.
- SAMe also acts as the main methylating agent in the liver.
- SAMe in vivo is associated with beneficial effects on liver function and structure and resulted in a corresponding attenuation of ethanol-induced liver injury as shown by less-striking glutathione depletion and lesser increases in plasma aspartate transaminase.
- SAMe also shows hepatocyte mitochondrial protection. As per the observation on rats, SAMe decreased ethanol-induced fat accumulation. Thus, SAMe was shown to be useful for opposing the oxidative stress and the alcohol-induced liver injury.
- Membrane alterations are common in alcoholic liver injury and are also associated with a decrease in phosphatidylcholine, the backbone of the membranes. SAMe increases phosphatidylcholine concentrations in the liver membranes by methylation reactions and thus protects hepatocytes from damages.
- Racemethionine to reduce the liver-toxic effects of hepatotoxins such as acetaminophen and methotrexate has led to the suggestion that it should be added to acetaminophen products. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress.
- the liver produces glutathione.
- Glutathione is important in the management of patients with alcoholic liver disease and viral hepatitis, particularly those with hepatitis C.
- Glutathione protects cells in several ways. It neutralizes oxygen molecules (free radicals) before they can harm cells. Together with selenium, it forms the enzyme glutathione peroxidase, which neutralizes hydrogen peroxide. It is also a component of another antioxidant enzyme, glutathione-S-transferase which is a broad-spectrum liver-detoxifying enzyme.
- Glutathione protects the body from free radical damages as it contains Sulphur donating amino acid- Cysteine (formed from methionine) which helps to destroy harmful toxic materials from the body. Cysteine also functions as an effective binder of harmful heavy metals in the body, the depletion of Cysteine -an essential part of Glutathione can result in frequent sicknesses and damages to the liver. Glutathione has several health benefits. Optimal amounts of glutathione are necessary for supporting the immune system, and, in particular, glutathione is required for replication of the lymphocyte immune cells. Glutathione also helps the liver to detoxify chemicals, such as acetaminophen, copper, and cadmium.
- Glutathione protects not only individual cells but also the tissues of the arteries, brain, heart, immune cells, kidneys, lenses of the eyes, liver, lungs, and skin against oxidant damage. It plays a role in preventing cancer, especially liver cancer, and may also have an anti-aging effect.
- Glutathione conjugation is an important step in detoxification process that produces water- soluble substances which are excreted via the kidneys.
- the elimination of fat-soluble compounds, especially heavy metals like mercury and lead, is dependent upon adequate levels of glutathione, which in turn is dependent upon adequate levels of methionine and cysteine.
- methionine and cysteine have a protective effect on glutathione and prevent depletion during toxic overload. This, in turn, protects the liver from the damaging effects of toxic compounds and promotes their elimination.
- Oxidative stress was shown to play a major pathogenic role in multiple disease states ranging from the hepatotoxicity of alcohol to the carcinogenicity of many compounds.
- the major natural defence mechanism against oxidative stress is reduced by glutathione, which traps the excess of free radicals.
- Glutathione The most important role of Glutathione in alcoholic liver disorders is following:
- cytochrome P4502E1 cytochrome P4502E1
- CYP2E1 activates some xenobiotics (such as acetaminophen) to toxic metabolites. It also generates several species of active oxygen species. Glutathione provides one of the cell's fundamental mechanisms for the scavenging of toxic free radicals.
- Alcohol causes liver disease through a variety of pathogenic mechanisms.
- the major mechanisms include interactions with nutrition and toxic manifestations through generation of oxidative stress and production of the toxic metabolite acetaldehyde.
- the combination of Racemethionine and Taurine shows a synergistic effect on targeted diseases.
- Racemethionine and Taurine are concentrated in liver and plays an important role in liver function, detoxification of harmful substances and hepatocyte protection. Many of their functions are independent of each other.
- taurine When taurine is used up for metabolic reactions, it is biosynthesized from methionine. Thus methionine is used up in this process. During stressed conditions or increased liver function requirements more and more methionine may be used up for taurine formation causing methionine depletion. Supplementation of taurine reduces the need for conversion of methionine to taurine thus allowing methionine for its other important functions especially for the liver protection.
- homocysteine levels may be associated with abnormal cardiovascular functions. It is found that taurine causes excretion of homocysteine via kidney and thus prevents its damages, if arty.
- Racemethionine and Taurine is a synergistic combination useful in various liver diseases and others.
- oral pharmaceutical composition of the present invention comprising dietary supplements, for replacing a necessary substance not found in large enough quantities in the diet, Preventing or decreasing the risk of developing a disease or condition, Boosting the immune system and improving general health, Boosting energy levels, Improving mental or physical performance, Reducing symptoms of a disease or health condition.
- the said composition also comprises dietary ingredients may include vitamins, minerals, herbs, amino acids, enzymes, organ tissues, glandulars, and metabolites. These are following -
- Chromium wherein it supports the bodies efforts to maintain normal glucose levels.
- the only "food” truly rich in Chromium is brewer's yeast, so it's rarely available in marketed products.
- Potassium wherein it is responsible for acid-base balance and osmotic pressure, Maintains proper function of cell walls in conjunction with sodium. Supports the activity of magnesium and Promotes cellular equilibrium thereof.
- Manganese wherein it Supports the maintenance of healthy bone mass and Supports the maintenance of a healthy reproductive system. It helps in the absorption of calcium and maintain bone mineral density.
- Zinc wherein Supports cell respiration, Supports the functions of antioxidants, Supports the immune system. It helps in the maintance of bone density .
- Biotin wherein the function is same as Vitamin B7, Supports muscles and the circulatory system. It helps in the maintance of body and beauty
- Vitamin K wherein it needed by the liver to produce a blood-clotting factor and for improving bone mineralisation.
- Vitamin C wherein improves body's ability to absorb calcium and iron, and excrete copper, lead and mercury; assists in absorption of certain amino acids, Converts cholesterol into bile acids, thereby lowering it in the body, Helps in neutralise nitrosamines (carcinogenic substances), Powerful antioxidant, supports immune system and its response to infections by boosting antibody function, Speeds healing of wounds and strengthens blood vessels. It helps in formation of collagen, a basic substance of connective tissue.
- Vitamin E has a great affinity for oxygen, it is so effective in preventing free radicals formation, Improves cell respiration and increases muscle efficiency, Protects fat-soluble vitamins; acts as an anti-coagulant, blood thinner, and helps to decrease cholesterol, Improves blood circulation and supports immune system, Involved in production of substance that delivers nerve impulses to muscles.
- Vitamin B6 is Important in many metabolic functions, including the release of glycogen from the liver when muscles need energy, Helps regulate body fluids by helping to balance potassium and sodium, This is also important for nerve and muscle function, Helps to synthesize red blood cells, Can help prevent formation of oxalic acid salts (lead to kidney stones) when combined with magnesium, Inhibits release of histamine beneficial for allergy sufferers. Also helps in the formation of certain neurotransmitters.
- Vitamin B3 (Niacin) wherein Assists in breaking down nutrients, Helps lower cholesterol and triglycerides and improves blood circulation, Vital to healthy nervous system, Releases histamine thereof.
- Vitamin Bl Thiamine wherein Helps to overcome stress and promotes a feeling of optimism, Stabilises the appetite and stomach secretions, Helps to maintain normal heart function, Important for growth and Improves nerve function.
- Vitamin B2 (Riboflavin) wherein Part of the enzyme system involved in breakdown of carbohydrates, fats, and proteins; also involved in synthesis of nucleic acids, Helps with Iron absorption, Key in regeneration of glutathione, an important antioxidant.
- Folic Acid wherein Along with B12, takes part in synthesis of nucleic acids, formation of red blood cells and certain amino acids, Stimulates stomach secretions and aids digestion, Helps body synthesise neurotransmitters; maintains nervous system. It maintains the concentration of homocystein.
- Vitamin D wherein Promotes the absorption of Calcium & Phosphorus, it helps assimilation.
- Vitamin A Maintains a healthy nervous system, normal heartbeat and efficient blood clotting.
- Vitamin B 12 (as cyanocobalamin) wherein Supports the development of red blood cells
- Above formulation is also protects chronic illness or malnutrition may be due to defective nutrition, wherein patient is not able to take vitamins / minerals / trace elements leads to poor performance of vital organs. It reduces lack of energy, due to poor eating. It will provide instant energy and work like prophylactic total health care.
- Vitamin B2 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5mg ( Riboflavin)
- Vitamin B3 2.5 mg 2.5 mg 2.5 mg 5mg 5mg ( Niacin )
- Vitamin B6 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg ( Pyridoxin )
- Vitamin B12 1.5 meg 1.5 meg 1.5 meg 1.5 meg 1.5 meg 1.5 meg (Cyanocobalamin)
- Pantothenic Acid 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention is based on a potent revital formulation which comprises two or more active ingredients such as taurine and racemethionine along with essential dietary supplements such as vitamins, iron, minerals, trace elements and pharmaceutically acceptable excipients preferably in oral dosage form.
Description
TITLE OF THE INVENTION- "POTENT REVITAL FORMULATION."
FIELD OF THE INVENTION- The present invention relates to efficient oral pharmaceutical composition which comprises main active ingredients such as taurine and race methionine along with multivitamins, minerals, trace elements some pharmaceutically acceptable excipients preferably in oral dosage form.
BACKGROUND OF THE INVENTION
Alcohol is a powerful liver toxin that harms (damages) the liver in three stages: alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. About 20 percent of alcoholics and heavy drinkers develop fatty liver, or steatosis. The rate of mortality in severe cases is about 50 percent. If heavy drinking continues, about 40 percent of cases of alcoholic hepatitis will develop into cirrhosis.
According to US Patent 5906811 wherein said The combination of several synergistic antioxidants, enzymatic co-factors and amino acids in appropriate delivery vehicles employed in aerosol carriers, mist and pump oral sprays, solutions, such as oral irrigators, mouth rinses and mouthwashes, or gels and solid compositions as a means of preventing and ameliorating signs and symptoms and complications to the oro-pharyngeal cavity and mouth including buccal mucosa, gums and tongue and the upper respiratory tract from damage caused by free radical species induced by tobacco smoke, smokeless tobacco, ingested or chewed noxious, malodorous or harmful substances and other inhaled environmental pollutants and particulate matter, including tobacco to secondary smokers.
According to United States Patent 5817695 wherein said A nutritional product is provided for cancer patients comprising, as per caloric requirement, a low concentration of carbohydrate, a high concentration of fat and an imbalance of amino acids wherein L-phenylalanine, L- tyrosine and L-methionine are present in the below normal concentrations and L-leucine is present in substantial excess of normal concentrations to suppress cancer growth and as an adjunct to conventional cancer therapies
According to European Patent EP1408988 wherein said Provided is a synergistic combination of nutritional supplements classified as Nutraceuticals and further combined
with antioxidant vitamins and minerals that, when orally administered to mammals, provides optimal delivery of vital metabolic precursors necessary for the production and repair of articular cartilage. Specifically provided is a unique combination of chondroitin sulfate sodium, methylsulfonylmethane, glucosamine potassium, glucosamine hydrochloride, glucosamine sulfate sodium, N-acetyl D-Glucosamine, sodium absorbate and chelated manganese proteinate compounded through agitation. The provided compositions and methods of administration are designed to effectively elevate and sustain blood levels of said compounds in turn enhancing the body's natural chondroprotective mechanisms while providing an efficient delivery mechanism which optimizes cellular uptake of glucosamine and chondroitin. This process of forming specified synergistic relationships between vital metabolic precursors increases the body's production of proteoglycans, chondrocytes, hyalauron glycosaminoglycans and collagen, facilitating the repair and regeneration of articular cartilage and symptomatic relief from pain and inflammation associated with articular degeneration.
According to WO 2006/062273 Al, wherein said the present invention relates to a health supplement food utilizing, in particular, branched amino acids from among essential amino acids. More specifically, the present invention relates to: a health supplement food comprising branched chain amino acids (herein after, referred to as LIV) composed of leucine (L), isoleucine (I) and valine (V) which is made to have a composition similar to essential amino acids contained in naturally-occurring milk, eggs, soybeans, beef and the like, and enhancing instant impact power under anaerobic conditions, via addition of L- glutamine and taurine which are essentially required when a person is exposed to excessive exercise, stress or overwork; a health supplement food for improving a weak constitution, comprising herbal materials such as ginseng, red ginseng and Acanthopanax; and a diet food or beverage further comprising dietary fibres such as insulin, polydextrose and crystalline cellulose, and carnitine and hydroxy citric acid.
According to WO 2007/115112 A2wherein said an exemplary dried, meat-based product includes meat and plant seed where the plant seed comprises at least approximately 3% caffeine by weight. For example, an exemplary product includes guarana plant seed. According to various products and processes, plant seed may be provided as a powder
According to US 2009/0005320 Al wherein said The invention relates to compositions comprising one or more ionic salts, each of said ionic salts consisting of a bicarbonate anion and a cation selected from the group consisting of an amino acid, an amino acid derivative, a di-peptide and a tri-peptide, and to methods of making and using said compositions.
Certain amino acids have found to play a promising role in preventing and treating a majority of these liver diseases due to their antitoxic and antioxidant properties. Racemethionine and Taurine are vital amongst them.
SUMMARY OF THE INVENTION
In one aspect, the invention is to provide commercially viable and efficient formulation.
In one aspect, the invention is to provide safe and effective dosage form with taurine and racemethionine composition and other ingredients such as multivitamins, minerals, trace elements which are using as dietery supplements.
In one aspect, the invention is to provide different release drug profile such as Sustained or controlled or retard formulation available in oral formulation (capsule, tablet, powder and in liquid thereof)
In one aspect, the invention is to protect chronic illness or malnutrition may be due to defective nutrition, wherein patient is not able to take vitamins/ minerals / trace elements leads to poor performance of vital organs.
In one aspect, it will provide instant energy and work like prophylactic total health care.
DETAILED DESCMPTION OF THE INVENTION
The invention will now be described in detail in connection with certain preferred and optional embodiments. So that various aspects thereof may be more fully understood and appreciated.
Generally liver protecting medication consists of amino acids, minerals, vitamins thereof can form spontaneously and are therefore thermodynamically stable.
The present invention discloses the efficiency pharmaceutical composition in oral dosage form. This comprises therapeutically effective amount of taurine, racemethionine multivitamins, minerals thereof so as to make the formulation stable.
According to the oral pharmaceutical composition of the present invention, the said oral pharmaceutical composition is available in various forms such as tablet, capsule, sachet, powder (liquid) thereof. It is useful supplementation in patients suffering from liver diseases and may also provide valuable benefits in patients suffering from cardiovascular diseases, diabetes, neurological disorders and others.
In preferred embodiment, Essential Amino Acids cannot manufacture these Amino Acids in body. These amino acids have antioxidant, antitoxic property which is useful in organ protection and detoxification of harmful substances. Racemethionine and Taurine are the examples of such amino acids.
In embodiment of the invention, Taurine, a liver protecting amino acid, It is essential for formation of bile acids and thus for detoxification processes, it reduces the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions. It is useful in treating people with alcohol dependency and is a detoxifying agent with antioxidant action that helps protect liver cells against various toxins.
In the case of liver health wherein Taurine is known that the liver is the main organ for taurine biosynthesis and also an important target organ for taurine's many biological activities. It is essential for formation of bile acids and thus for detoxification processes.
In a clinical study, taurine has been shown to reduce the secretion of apolipoprotein B100 and lipids in Hepatic G2 cells and is effective in removing fatty liver deposits, preventing liver disease, and reducing cirrhosis. Importantly taurine has protective and preventive role in portal hypertension, the major cause of death in cirrhotic liver conditions.
Taurine plays following important roles in hepatoprotection -
-It Combines and removes of toxic chemicals and metabolites.
-Antioxidant action
-Taurine increases levels of antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and ROS induced damages
-As essential component of cell membranes wherein it enhances transport of important ions across hepatocytes thus improving their functions and recovery. A deficiency of taurine can lead to electrolyte imbalance due to impaired mineral transport across cell membranes and this reduces the ability of the liver to remove toxic substances.
The inclusion of taurine in a liver supplementation is beneficial for the above reasons.
In the case of Taurine deficiency and liver injuries (study on mice) wherein Taurine deficiency can trigger hepatitis and liver fibrosis, probably due to a diminished antioxidant defence, increase in inflammatory reactions and mitochondrial dysfunction in hepatocytes.
Taurine deficiency increases free radicals
ROS mediated oxidative damages and formation of toxic metabolites in liver cells. This can be seen as there is a 6-fold increase in the TNFA plasma levels. Tissue necotising factor alpha is a marker for inflammatory processes that leads to cell death. Taurine supplementation prevents these damages and protects cells.
Severe toxicities cause death of more and more hepatocytes. These cells are replaced by formation of new cells. If the cell destruction is high, the newly formed cells are immature and abnormal in shape (oval shape). Development of these cells is associated with liver dysfunction..
Taurine protects liver tissue from necrosis (cell death), inflammation, and fibrosis, and helps protect cells from damage.
This effect is observed in a rat study which used carbon tetrachloride as toxicant. Taurine pre- treatment induced a marked beneficial effect regarding the prevention of hepatocellular necrosis and atrophy as demonstrated morphologically. In conclusion, these results suggest that taurine pre-treatment prevents the morphologic damage caused by CC14 in the early stages.
Further taurine helps for normal hepatocyte structures and prevents formation of extracellular matrix which otherwise leads to liver fibrosis.
Taurine in alcoholic liver disorders wherein Taurine reverses the hepatic steatosis (deposition of fat) and lipid peroxidation caused by chronic alcohol consumption in rats
As per clinical study, Taurine has been shown to be useful in treating people with alcohol dependency involving over 3,000 alcohol dependent people who were given taurine showed that taurine is more effective than placebo at preventing alcohol relapse.
Taurine increases urine excretion of homocysteine during alcohol withdrawal. Rise in blood homocysteine (hyperhomocysteinaemia) was observed in chronic alcoholics who underwent withdrawal from alcohol. Homocysteine has excitatory effects in brain and is associated with nervous restlessness and other psychotic episodes seen during alcohol withdrawal. Taurine being an inhibitory neurotransmitter reduces excitatory signals. It also reduces hyperhomocysteinaemia by excreting homocysteine through kidneys. This dual effect helps in alcohol withdrawal.
Twenty-two patients undergoing treatment for alcohol withdrawal were given 1 gram of taurine three times per day orally for seven days. When compared to retrospective controls, significantly fewer of the taurine-treated patients had psychotic episodes (14% vs. 45%, p < 0.05). The number of psychotic cases after admission who had also been psychotic before admission was 1/16 for the taurine group and 11/17 for the controls (p < 0.001).
The inhibitory amino acid taurine may constitute an important protective mechanism against excitotoxicity and thus protects against neuronal damage.
In embodiment of the invention, racemethionine (2-amino-4-methylsulfanylbutanoic acid (C5H11N02S) is a lipotropic amino acid in hepatoprotection. It is a potent methyl donor, powerful antioxidant and a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe).
Racemethionine is also the precursor for taurine and thus its levels are reduced due to consumption for formation of taurine. Taurine supplementation along with methionine increases liver taurine levels and spares methionine for other vital functions. This makes the combination of Taurine and Methionine as a viable (effective) combination with synergistic action.
It contains Methionine which has Methyl (-CH3) donor important in metabolic processes where methyl group is transferred to other compound (methylation). A precursor to other important substances like S-adenosyl methionine (SAMe), glutathione and amino acids like taurine and cysteine. Methionine levels determine the liver's concentration of sulfur- containing antioxidant compounds like SAMe and glutathione which improve and normalize liver functions. Methionine itself has a protective effect on glutathione and prevents depletion during toxic overload, which can protect the liver from the damaging effects of toxic compounds. Methionine residues on the surface of proteins (like enzymes) offer antioxidant protection and thus prevent degradation of proteins by reactive oxygen species and free radicals. Liver contains maximum amounts of enzymes and thus methionine concentration in liver is important for protection against toxic free radicals.
In the case of Liver protection wherein Cells in the liver and kidneys especially need methionine for regeneration. It helps in protection against the destruction of delicate liver tissues. Methionine helps maintain the health of the liver by removing toxins and giving protection.
In the case of Alcoholic liver disorder wherein Alcohol is a major cause of liver disease and disrupts methionine and oxidative balances.
As per the clinical trials on rats following steps obtained
Alcohol feeding to rats that were submitted to a jejunoileal bypass operation has been shown to result in liver damage being comparable with alcohol-induced liver disease in man.
In a study, a striking effect of free methionine consumption on histological liver injury, triglyceride accumulation, and energy-rich nucleoside content in the liver of rats with a jejunoileal bypass is demonstrated.
Methionine was found to strongly improve the alcohol-induced histological changes in the liver. Triglyceride content of the liver was found to decrease in a dose-dependent manner with increasing methionine ingestion.
Hepatic adenosine triphosphate content increased significantly with higher methionine consumption.
These results underscore the impairment of the transmethylation/transsulfuration pathway in the development of alcohol-induced liver diseases.
Due to above observation, its clarify that Methionine is the precursor for other important antioxidant substances like SAMe and glutathione.
SAMe is an active compound made from methionine and adenosine triphosphate (ATP). It acts as a methyl donor in a variety of biochemical pathways. Methylation reactions are essential for the detoxification of harmful products of metabolism, and the synthesis of numerous physiological agents including neurotransmitters, cartilage, and glutathione. The role of SAMe for intrahepatic cholestasis associated with liver disease has been observed.
In the case of liver protection wherein SAMe improves and normalizes liver function. SAMe is used in the treatment of cirrhosis and liver damage caused by alcohol. Through methylation, SAMe increases membrane fluidity, restoring several factors that promote bile flow. Treatment with SAMe helps decrease serum bilirubin (pigment in the blood that can cause jaundice) in patients with elevated serum bilirubin level.
In the case of alcoholic liver disorder wherein SAMe is to be useful therapeutically in alcoholic liver injury including cholestasis, and in the devastating consequences of excessive liver fibrosis (leading to cirrhosis).
S-Adenosyl-L-methionine (SAMe) exerts major key functions in the liver, including serving as a precursor for cysteine and glutathion. SAMe is particularly important in opposing the toxicity of free oxygen radicals generated by various pathogens, including alcohol, which
causes oxidative stress largely by the induction of cytochrome P4502E1 (CYP2E1) and by its metabolite acetaldehyde. SAMe also acts as the main methylating agent in the liver.
SAMe in vivo is associated with beneficial effects on liver function and structure and resulted in a corresponding attenuation of ethanol-induced liver injury as shown by less-striking glutathione depletion and lesser increases in plasma aspartate transaminase. SAMe also shows hepatocyte mitochondrial protection. As per the observation on rats, SAMe decreased ethanol-induced fat accumulation. Thus, SAMe was shown to be useful for opposing the oxidative stress and the alcohol-induced liver injury.
Membrane alterations are common in alcoholic liver injury and are also associated with a decrease in phosphatidylcholine, the backbone of the membranes. SAMe increases phosphatidylcholine concentrations in the liver membranes by methylation reactions and thus protects hepatocytes from damages.
The ability of Racemethionine to reduce the liver-toxic effects of hepatotoxins such as acetaminophen and methotrexate has led to the suggestion that it should be added to acetaminophen products. It is thought that metabolism of high doses of acetaminophen in the liver lead to decreased levels of hepatic glutathione and increased oxidative stress.
The liver produces glutathione. A deficiency of hepatic GSH and other antioxidants and/or an increase in oxidative stress, may contribute to the progression of liver disease. Glutathione is important in the management of patients with alcoholic liver disease and viral hepatitis, particularly those with hepatitis C.
Glutathione protects cells in several ways. It neutralizes oxygen molecules (free radicals) before they can harm cells. Together with selenium, it forms the enzyme glutathione peroxidase, which neutralizes hydrogen peroxide. It is also a component of another antioxidant enzyme, glutathione-S-transferase which is a broad-spectrum liver-detoxifying enzyme.
Glutathione protects the body from free radical damages as it contains Sulphur donating amino acid- Cysteine (formed from methionine) which helps to destroy harmful toxic materials from the body. Cysteine also functions as an effective binder of harmful heavy metals in the body, the depletion of Cysteine -an essential part of Glutathione can result in frequent sicknesses and damages to the liver.
Glutathione has several health benefits. Optimal amounts of glutathione are necessary for supporting the immune system, and, in particular, glutathione is required for replication of the lymphocyte immune cells. Glutathione also helps the liver to detoxify chemicals, such as acetaminophen, copper, and cadmium.
Glutathione protects not only individual cells but also the tissues of the arteries, brain, heart, immune cells, kidneys, lenses of the eyes, liver, lungs, and skin against oxidant damage. It plays a role in preventing cancer, especially liver cancer, and may also have an anti-aging effect.
Glutathione conjugation is an important step in detoxification process that produces water- soluble substances which are excreted via the kidneys. The elimination of fat-soluble compounds, especially heavy metals like mercury and lead, is dependent upon adequate levels of glutathione, which in turn is dependent upon adequate levels of methionine and cysteine. When increased levels of toxic compounds are present, more methionine is utilized for cysteine and glutathione synthesis. Methionine and cysteine have a protective effect on glutathione and prevent depletion during toxic overload. This, in turn, protects the liver from the damaging effects of toxic compounds and promotes their elimination.
Oxidative stress was shown to play a major pathogenic role in multiple disease states ranging from the hepatotoxicity of alcohol to the carcinogenicity of many compounds. The major natural defence mechanism against oxidative stress is reduced by glutathione, which traps the excess of free radicals. The most important role of Glutathione in alcoholic liver disorders is following:
The microsomal ethanol-oxidizing system has been the subject of extensive research. A 4- fold induction of cytochrome P4502E1 (CYP2E1) was found in liver biopsy samples from recently alcohol drinking subjects. CYP2E1 activates some xenobiotics (such as acetaminophen) to toxic metabolites. It also generates several species of active oxygen species. Glutathione provides one of the cell's fundamental mechanisms for the scavenging of toxic free radicals.
Alcohol causes liver disease through a variety of pathogenic mechanisms. The major mechanisms include interactions with nutrition and toxic manifestations through generation of oxidative stress and production of the toxic metabolite acetaldehyde.
The combination of Racemethionine and Taurine shows a synergistic effect on targeted diseases.
Both Racemethionine and Taurine are concentrated in liver and plays an important role in liver function, detoxification of harmful substances and hepatocyte protection. Many of their functions are independent of each other.
When taurine is used up for metabolic reactions, it is biosynthesized from methionine. Thus methionine is used up in this process. During stressed conditions or increased liver function requirements more and more methionine may be used up for taurine formation causing methionine depletion. Supplementation of taurine reduces the need for conversion of methionine to taurine thus allowing methionine for its other important functions especially for the liver protection.
Further, in some patients excess methionine has been reported to increase homocysteine levels. Increased homocysteine levels may be associated with abnormal cardiovascular functions. It is found that taurine causes excretion of homocysteine via kidney and thus prevents its damages, if arty.
Thus the combination of Racemethionine and Taurine is a synergistic combination useful in various liver diseases and others.
Thus according to preferred aspect, oral pharmaceutical composition of the present invention comprising dietary supplements, for replacing a necessary substance not found in large enough quantities in the diet, Preventing or decreasing the risk of developing a disease or condition, Boosting the immune system and improving general health, Boosting energy levels, Improving mental or physical performance, Reducing symptoms of a disease or health condition.
In another embodiment of the present invention the said composition also comprises dietary ingredients may include vitamins, minerals, herbs, amino acids, enzymes, organ tissues, glandulars, and metabolites. These are following -
Selenium Wherein it acts as an anti-oxidant and protects from free radicals supports the functions of anti-oxidants.
Chromium wherein it supports the bodies efforts to maintain normal glucose levels.
The only "food" truly rich in Chromium is brewer's yeast, so it's rarely available in marketed products.
Potassium wherein it is Responsible for acid-base balance and osmotic pressure, Maintains proper function of cell walls in conjunction with sodium. Supports the activity of magnesium and Promotes cellular equilibrium thereof.
Magnesium wherein its Primary function is enzyme activation, Supports the maintenance of a healthy heart. It has a critical role in energy production, Important to the metabolically active tissues, mainly found in bone, muscles and vital organs. It is also prevents bone loss.
Manganese wherein it Supports the maintenance of healthy bone mass and Supports the maintenance of a healthy reproductive system. It helps in the absorption of calcium and maintain bone mineral density.
Zinc wherein Supports cell respiration, Supports the functions of antioxidants, Supports the immune system. It helps in the maintance of bone density .
Copper wherein it supports the maintenance of healthy cell respiration and the functioning of antioxidants. It helps in protection against free radicals.
Biotin wherein the function is same as Vitamin B7, Supports muscles and the circulatory system. It helps in the maintance of body and beauty
Vitamin K wherein it needed by the liver to produce a blood-clotting factor and for improving bone mineralisation.
Vitamin C wherein improves body's ability to absorb calcium and iron, and excrete copper, lead and mercury; assists in absorption of certain amino acids, Converts cholesterol into bile acids, thereby lowering it in the body, Helps in neutralise nitrosamines (carcinogenic substances), Powerful antioxidant, supports immune system and its response to infections by boosting antibody function, Speeds healing of wounds and strengthens blood vessels. It helps in formation of collagen, a basic substance of connective tissue.
Vitamin E has a great affinity for oxygen, it is so effective in preventing free radicals formation, Improves cell respiration and increases muscle efficiency, Protects fat-soluble
vitamins; acts as an anti-coagulant, blood thinner, and helps to decrease cholesterol, Improves blood circulation and supports immune system, Involved in production of substance that delivers nerve impulses to muscles.
Vitamin B6 (Pyridoxine) is Important in many metabolic functions, including the release of glycogen from the liver when muscles need energy, Helps regulate body fluids by helping to balance potassium and sodium, This is also important for nerve and muscle function, Helps to synthesize red blood cells, Can help prevent formation of oxalic acid salts (lead to kidney stones) when combined with magnesium, Inhibits release of histamine beneficial for allergy sufferers. Also helps in the formation of certain neurotransmitters.
Vitamin B3 (Niacin) wherein Assists in breaking down nutrients, Helps lower cholesterol and triglycerides and improves blood circulation, Vital to healthy nervous system, Releases histamine thereof.
Vitamin Bl (Thiamine) wherein Helps to overcome stress and promotes a feeling of optimism, Stabilises the appetite and stomach secretions, Helps to maintain normal heart function, Important for growth and Improves nerve function.
Vitamin B2 (Riboflavin) wherein Part of the enzyme system involved in breakdown of carbohydrates, fats, and proteins; also involved in synthesis of nucleic acids, Helps with Iron absorption, Key in regeneration of glutathione, an important antioxidant.
Folic Acid wherein Along with B12, takes part in synthesis of nucleic acids, formation of red blood cells and certain amino acids, Stimulates stomach secretions and aids digestion, Helps body synthesise neurotransmitters; maintains nervous system. It maintains the concentration of homocystein.
Vitamin D wherein Promotes the absorption of Calcium & Phosphorus, it helps assimilation.
Vitamin A, Maintains a healthy nervous system, normal heartbeat and efficient blood clotting.
Vitamin B 12 (as cyanocobalamin) wherein Supports the development of red blood cells,
Supports the nervous system, Supports the digestive system, and Supports the production of bone marrow.
Calcium wherein Supports the maintenance of healthy bone mass ,helps in the performance of nervous system, blood coagulation, synthesis of neurotransmitters.
Above formulation is also protects chronic illness or malnutrition may be due to defective nutrition, wherein patient is not able to take vitamins / minerals / trace elements leads to poor performance of vital organs. It reduces lack of energy, due to poor eating. It will provide instant energy and work like prophylactic total health care.
EXAMPLES-
Vitamin B2 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5mg ( Riboflavin)
Vitamin B3 2.5 mg 2.5 mg 2.5 mg 5mg 5mg ( Niacin )
Vitamin B6 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg ( Pyridoxin )
Folic Acid 100 meg 100 meg 100 meg 100 meg 100 meg
Vitamin B12 1.5 meg 1.5 meg 1.5 meg 1.5 meg 1.5 meg (Cyanocobalamin)
Biotin 7.5 meg 7.5 meg 7.5 meg 7.5 meg 7.5 meg
Pantothenic Acid 2.5 mg 2.5 mg 2.5 mg 2.5 mg 2.5 mg
Phosphorus 35 mg 35 mg 35 mg 27.25mg 25mg
Iodine 37.5 meg 37.5 meg 37.5 meg 37.5 meg 37.5mcg
Calcium 84 mg 84 mg 84 mg 84 mg 84mg
Magnesium 25 mg 25 mg 25 mg 25 mg 25 mg
Selenium 10 meg 10 meg 10 meg 17.5 meg 10 meg
Manganese 0.5 mg 0.5 mg 0.5 mg 0.5 mg 0.5 mg
Chromium 30 meg 30 meg 30 meg 30 meg 30 meg
Molybdenum 18.75 meg 18.75 meg 18.75 meg 18.75 meg 18.75 meg
Potassium 20 mg 20 mg 20 mg 20 mg 20 mg
Lycopene 0.075 mg 0.075 mg 0.075 mg 0.075 mg 0.075 mg
DHA 25 mg 25 mg 25 mg 25 mg 25 mg
Rosemary 1 mg 1 mg 1 mg 1 mg 1 mg
EPA 25 mg 25 mg 25 mg 25 mg 25 mg
Claims
1. Potent revital oral formulation comprises two or more active ingredients such as taurine and racemethionine along with essential dietary supplements such as vitamins, iron, minerals, trace elements and pharmaceutical acceptable excipients.
2. Potent revital oral formulation as claimed in claim 1 wherein it is available in various forms such as tablet, capsule, sachet, and powder, liquid thereof.
3. Potent revital oral formulation as claimed in claim 1 wherein racemethionine is a lipotropic amino acid in hepatoprotection. It is a potent methyl donor, powerful antioxidant and a major source of other liver detoxificants including glutathione and S-Adenosyl Methionine (SAMe).
4. Potent revital oral formulation as claimed in claim 3 wherein that Methionine is the precursor for other important antioxidant substances like SAMe and glutathione .
5. Potent revital oral formulation as claimed in claim 3 & 4 wherein SAMe improves and normalizes liver function. SAMe is used in the treatment of cirrhosis and liver damage caused by alcohol.
6. Potent revital oral formulation as claimed in claim 1 wherein Taurine increases levels of antioxidant enzymes like glutathione peroxidase, superoxide dismutase and catalase in liver and thus protects hepatocytes from free radical and .ROS induced damages.
7. Potent revital oral formulation as claimed in claim 1 wherein Both Racemethionine and Taurine are concentrated in liver and play important role in liver function, detoxification of harmful substances and hepatocyte protection. Many of their functions are independent of each other.
8. Potent revital oral formulation as claimed in claim 1 wherein Selenium acts as an anti-oxidant and Supports the functions of anti-oxidants.
9. Potent revital oral formulation as claimed in claim 1 wherein Chromium supports the bodies efforts to maintain normal glucose levels.
10. Potent revital oral formulation as claimed in claim 1 wherein Potassium is Responsible for acid-base balance and osmotic pressure, Maintains proper function of cell walls in conjunction with sodium. Supports the activity of magnesium and Promotes cellular equilibrium thereof.
11. Potent revital oral formulation as claimed in claim 1 wherein Magnesium is Primary function as enzyme activation, Supports the maintenance of a healthy heart. It has a critical role in energy production, Important to the metabolically active tissues, mainly found in bone, muscles and vital organs. It is also maintained bone mineralisation.
12. Potent revital oral formulation as claimed in claim 1 wherein Manganese wherein it Supports the maintenance of healthy bone mass and Supports the maintenance of a healthy reproductive system. It maintained bone mineral density also.
13. Potent revital oral formulation as claimed in claim 1 wherein Zinc wherein Supports cell respiration, Supports the functions of antioxidants, Supports the immune system.
14. Potent revital oral formulation as claimed in claim 1 wherein Copper supports the maintenance of healthy cell respiration and the functioning of antioxidants.
15. Potent revital oral formulation as claimed in claim 1 wherein Biotin wherein the function is same as Vitamin B7, Supports muscles and Supports the circulatory system.
16. Potent revital oral formulation as claimed in claim 1 wherein Vitamin needed by the liver to produce a blood-clotting factor and for improving bone mineralisation.
17. Potent revital oral formulation as claimed in claim 1 wherein Vitamin C improves body's ability to absorb calcium and iron, and excrete copper, lead and mercury; assists absorption of certain amino acids, Converts cholesterol into bile acids, thereby lowering it in the body, Helps neutralise nitrosamines (carcinogenic substances), Powerful antioxidant; supports immune system and its response to infections by boosting antibody function, Speeds healing of wounds and strengthens blood vessels. It helps in formation of collagen, basic substance of connective tissue.
18. Potent revital oral formulation as claimed in claim 1 wherein Vitamin E has a great affinity for oxygen, it is so effective in preventing free radical formation, Improves cell respiration and increases muscle efficiency, Protects fat-soluble vitamins; acts as an anti-coagulant, blood thinner, and helps to decrease cholesterol, Improves blood circulation and supports immune system, Involved in production of substance that delivers nerve impulses to muscles.
19. Potent revital oral formulation as claimed in claim 1 wherein Vitamin B6 (Pyridoxine) Important in many metabolic functions, including the release of glycogen from the liver when muscles need energy, Helps regulate body fluids by helping to balance potassium and sodium, This is also important for nerve and muscle function, Helps to synthesize red blood cells, it Can help prevents formation of oxalic acid salts (lead to kidney stones) when combined with magnesium, Inhibits release of histamine beneficial for allergy sufferers.
20. Potent revital oral formulation as claimed in claim 1 wherein Vitamin B3 (Niacin) Assists in breaking down nutrients, Helps in lower cholesterol and triglycerides and improves blood circulation, Vital to healthy nervous system, Releases histamine thereof.
21. Potent revital oral formulation as claimed in claim I wherein Vitamin Bl (Thiamine) helps to overcome stress and promotes a feeling of optimism, Stabilises the appetite and stomach secretions, Helps to maintain normal heart function, Important to growth and Improves nerve function.
22. Potent revital oral formulation as claimed in claim 1 wherein Vitamin B2 (Riboflavin) Part of the enzyme system involved in breakdown of carbohydrates, fats, and proteins; also involved in synthesis of nucleic acids, Helps with Iron absorption, Key in regeneration of glutathione, an important antioxidant
23. Potent revital oral formulation as claimed in claim 1 wherein Folic Acid Along with B12, takes part in synthesis of nucleic acids, formation of red blood cells and certain amino acids, Stimulates stomach secretions and aids digestion, Helps body synthesise neurotransmitters; maintains nervous system. It maintains the concentration of homocystein, prevent development of hypertension.
24. Potent revital oral formulation as claimed in claim 1 wherein Vitamin D promotes the absorption of Calcium & Phosphorus, Helps in assimilation.
25. Potent revital oral formulation as claimed in claim 1 wherein Vitamin A, Maintains a healthy nervous system, normal heartbeat and efficient blood clotting.
26. Potent revital oral formulation as claimed in claim 1 wherein Vitamin B12 (as cyanocobalamin) Supports the development of red blood cells, Supports the nervous system, Supports the digestive system, and Supports the production of bone marrow. It maintains the myelin sheath of neurones also.
27. Potent revital oral formulation as claimed in claim 1 wherein Calcium Supports the maintenance of healthy bone mass ,helps in the performance of nervous system, blood coagulation, synthesis of neurotransmitters.
28. Potent revital oral formulation as claimed in claim 1 wherein It protects chronic illness or malnutrition may be due to defective nutrition, wherein patient is not able to take vitamins / minerals / trace elements leads to poor performance of vital organs. It reduces lack of energy, due to poor eating. It will provide instant energy and work like prophylactic total health care.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN496MU2012 | 2012-02-23 | ||
IN496/MUM/2012 | 2012-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013124860A1 true WO2013124860A1 (en) | 2013-08-29 |
Family
ID=48407756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2013/000020 WO2013124860A1 (en) | 2012-02-23 | 2013-01-10 | Potent revital formulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013124860A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015177805A1 (en) * | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combination of taurine and racemethionine for treatment of liver diseases |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
EP1408988A1 (en) | 1999-11-02 | 2004-04-21 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
JP2004194616A (en) * | 2002-12-20 | 2004-07-15 | Creatis Dam:Kk | Health food product containing young barley leaf powder extract and fresh water clam extract |
WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
WO2007115112A2 (en) | 2006-03-29 | 2007-10-11 | Brian Levin | Dried meat products including at least one stimulant |
WO2007114945A2 (en) * | 2006-04-04 | 2007-10-11 | Hill's Pet Nutrition, Inc. | Compositions and methods for enhancing the antioxidant status of animals |
US20090005320A1 (en) | 2008-09-02 | 2009-01-01 | Bruce Kneller | Compositions comprising amino acid bicarbonate and methods of use thereof |
WO2011045810A1 (en) * | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
-
2013
- 2013-01-10 WO PCT/IN2013/000020 patent/WO2013124860A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451341B1 (en) * | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
US5817695A (en) | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
EP1408988A1 (en) | 1999-11-02 | 2004-04-21 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
JP2004194616A (en) * | 2002-12-20 | 2004-07-15 | Creatis Dam:Kk | Health food product containing young barley leaf powder extract and fresh water clam extract |
WO2006062273A1 (en) | 2004-12-10 | 2006-06-15 | Se-Gyu Kim | Branched-amino acid supplement food |
WO2007115112A2 (en) | 2006-03-29 | 2007-10-11 | Brian Levin | Dried meat products including at least one stimulant |
WO2007114945A2 (en) * | 2006-04-04 | 2007-10-11 | Hill's Pet Nutrition, Inc. | Compositions and methods for enhancing the antioxidant status of animals |
US20090005320A1 (en) | 2008-09-02 | 2009-01-01 | Bruce Kneller | Compositions comprising amino acid bicarbonate and methods of use thereof |
WO2011045810A1 (en) * | 2009-08-13 | 2011-04-21 | Zota Health Care Limited | Pharmaceutical compositions containing taurine and race-methionine for the treatment of alcoholism |
Non-Patent Citations (1)
Title |
---|
CHARLES S LIEBER: "Liver Diseases by Alcohol and Hepatitis C: Early Detection and New Insights in Pathogenesis Lead to Improved Treatment", AMERICAN JOURNAL OF ADDICTIONS, AMERICAN PSYCHIATRIC PRESS, WASHINGTON, DC, US, vol. 10, no. SUPPL. S1, 1 January 2001 (2001-01-01), pages S29 - S50, XP002629097, ISSN: 1055-0496, [retrieved on 20100218], DOI: 10.1080/10550490150504128 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015177805A1 (en) * | 2014-05-19 | 2015-11-26 | Zota Health Care Ltd | Combination of taurine and racemethionine for treatment of liver diseases |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7429569B2 (en) | Compositions and methods for the regulation of homocysteine levels within the body | |
JPH09504036A (en) | Dietary supplements that optimize cell health | |
US6555141B1 (en) | L-ergothioneine, Milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage | |
GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
CN112654264A (en) | Using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+Composition and method of precursors | |
MX2010009015A (en) | Leaves extract of panax sp., a process of making the same and uses thereof. | |
US9877939B2 (en) | Composition and methods for the production of S-adenosylmethionine within the body | |
US20050013884A1 (en) | Compositions and methods for treating heart disease | |
WO2008095093A2 (en) | Method of increasing cellular function and health of glutathione deficient animals | |
GB2585619A (en) | A supplement | |
Kalman | Exercise Studies | |
US20150328176A1 (en) | Composition for treatment of neurodegenerative disease | |
KR20120010680A (en) | A functional beverage composition comprising taurine, L-carnitine, vitamin C, vitamine B complex, and color selected from caramel color and sepia color | |
Devi et al. | Protective effect of Premna tomentosa extract (L. verbanacae) on acetaminophen-induced mitochondrial dysfunction in rats | |
US6369041B2 (en) | Oral combinations of hydroxocobalamin and folic acid | |
WO2013124860A1 (en) | Potent revital formulation | |
US20030194453A1 (en) | Dietary supplement | |
Klatz | The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You | |
Ojo et al. | Effects of pre-induction administration of Allium sativum on some biochemical parameters in alloxan induced diabetic rats | |
GB2600668A (en) | Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection. | |
Mullen et al. | Potential new therapies for alcoholic liver disease | |
Todorović et al. | Roles of sulfur-containing amino acids in gastrointestinal physiology and pathophysiology | |
RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
KR100515923B1 (en) | The bio conjugated proteins is process of produce | |
KR100309715B1 (en) | Composition having function for preventing toxicity and hangover of alcohol by activation of citric acid cycle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13721809 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13721809 Country of ref document: EP Kind code of ref document: A1 |